AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer
AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United S...
AstraZeneca faces state funding blow at Merseyside project
AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the ...
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
AstraZeneca's CEO has a vision for the weight loss drugs market. There probably won't be one medicine that's useful in every niche.
AstraZeneca shows promise in phase III study
A new combination treatment has shown significant improvement in treating chronic lymphocytic leukaemia (CLL) in a recent clinical trial. The AMPLIFY Phase III study found that a fixed duration of ...
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca PLC NASDAQ: AZN is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed ...
AstraZeneca ups annual guidance as first half half revenues surge
AstraZeneca PLC (LSE:AZN) has raised its guidance for revenue and earnings this year after first-half sales jumped by 18%. Pascal Soriot, chief executive, said: "Building on our strong growth in t...
AstraZeneca lifts full-year outlook on upbeat demand for therapies
Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for canc...
AstraZeneca could upgrade expectations after setting out bold growth plans
AstraZeneca PLC (LSE:AZN) releases its quarterly results next Thursday in the wake of an Investor Day at which outlined its bold plan to almost double its turnover to $80 billion by the end of the ...
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
AstraZeneca Closes Acquisition of Amolyt Pharma
LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endoc...
AstraZeneca has a 'catalyst-rich' period ahead
British pharmaceuticals megacap AstraZeneca PLC (LSE:AZN) shares surged nearly a percentage point higher on Friday, reflecting what broker Shroe Capital Markets sees as a “catalyst-rich period ahea...
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.
Aptamer Group up 12% on AstraZeneca collaboration
Shares of Aptamer Group PLC (AIM:APTA) were up 12% after announcing a new collaboration with AstraZeneca PLC (LSE:AZN) to explore the use of Optimer technology for targeted delivery of siRNA, a typ...
AstraZeneca's COVID prevention drug application gets EU fast-track assessment
AstraZeneca said on Monday the EU drug regulator has accepted a market authorisation application for its investigational COVID-19 prevention drug, Sipavibart, under an accelerated assessment.
Related Companies